Completed PHASE4 INTERVENTIONAL 3-arm NCT02417597

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)

Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years

Sponsor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Conditions Hepatitis E

Interventions Recombinant Hepatitis E Vaccine (Escherichia Coli)

Updated 5 times since 2017 Last updated: May 17, 2016 Started: Apr 30, 2015 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02417597, this PHASE4 trial focuses on Hepatitis E and remains completed. Sponsored by Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., it has been updated 5 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Xiamen Innovax Biotech Co., Ltd
Xiamen University

Data source: Xiamen Innovax Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Quzhou, China